Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions-Reference-Cited by-同舟云学术

Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions

Published:2022-01-07 Issue:7 Volume:28 Page:1131-1137
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

Cohen Jeffrey A¹^ORCID,Bermel Robert A¹^ORCID,Grossman Cynthia I²,Hersh Carrie M³^ORCID,Hyland Megan⁴,Mowry Ellen M⁵,Naismith Robert⁶^ORCID,Naylor Maria L²^ORCID,Nicholas Jacqueline⁷,Rajbhandar Rajani²,Singh Carol M²,Tintorè Mar⁸^ORCID,Zabalza Ana⁸^ORCID,Ziemssen Tjalf⁹^ORCID,Williams James R²,Montalban Xavier⁸

Affiliation:

1. Mellen Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA

2. Biogen, Cambridge, MA, USA

3. Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV, USA

4. Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA

5. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

6. Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA

7. OhioHealth Multiple Sclerosis Center, Riverside Methodist Hospital, Columbus, OH, USA

8. Centre d’Esclerosi Múltiple de Catalunya, Department of Neurology and Neuroimmunology, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain

9. Multiple Sclerosis Center Dresden, Center of Clinical Neuroscience, Department of Neurology, University Clinic Carl-Gustav Carus, Dresden, Germany

Abstract

Background: The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain. Methods: Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response. Results: Three hundred twenty-two people with MS were included; 91.9% received an mRNA vaccine. Post-vaccination reactive IgG rates (IgG index > 1) were 40% for anti-CD20 (32/80 patients); 41% for sphingosine 1-phosphate receptor modulators (S1PRM, 16/39); and 100% for all other classes, including the no DMT group. Conclusion: Anti-CD20 therapies and S1PRMs reduce IgG response to SARS-CoV-2 vaccination; IgG response is preserved with other DMTs.

Funder

Biogen

Publisher

SAGE Publications

Subject

Neurology (clinical),Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/13524585211061343

Reference14 articles.

1. Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis

2. MS International Federation. Global COVID-19 advice for people with MS, 2020, http://www.msif.org/wp-content/uploads/2020/06/MSIF-Global-advice-on-COVID-19-for-people-with-MS-_-updated17June2020.pdf (accessed 21 October 2020).

3. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

4. Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era

5. Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability;Drugs;2024-03

2. Era of COVID-19 in Multiple Sclerosis Care;Neurologic Clinics;2024-02

3. Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity;Multiple Sclerosis Journal;2023-11-09

4. Humoral immune response after Ad26.COV2.S vaccination in patients with multiple sclerosis treated with natalizumab;Multiple Sclerosis Journal - Experimental, Translational and Clinical;2023-10

5. Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies;Journal of Neurology;2023-08-17